BrightFocus® Foundation

Cure in Mind. Cure in Sight.

Sparking Discovery.

Innovative science to impact lives.

2016 ANNUAL REPORT

Alzheimer's Disease Research
Macular Degeneration Research
National Glaucoma Research

Table of contents:

Dear Friends,

At BrightFocus Foundation we continue to expand our support for bold, innovative science around the world through our three research programs: **Alzheimer's Disease Research, Macular Degeneration Research,** and **National Glaucoma Research**. In 2016 we awarded $11.7 million in new research grants, a record amount toward our mission of ending Alzheimer's disease, macular degeneration, and glaucoma.

Our researchers are at the forefront of scientific discovery, pushing new frontiers of knowledge in their labs and sparking creativity and innovation through prominent roles and awards at major scientific conferences and journals.

At the same time, we continue to reach larger audiences—both families impacted by these diseases who use our expanded digital and print resources, as well as policy and thought leaders across the public and private sectors.

We are driven by a fierce sense of urgency to find cures for age-related diseases—for the first time in history the world will soon have more people over age 65 than under age 5. It is imperative that we change the trajectory of these diseases. This is why our world-class Scientific Review Committees are so dedicated and demanding in identifying the most promising science.

We were recently honored to host our inaugural ***An Evening of BrightFocus***, a Washington, DC event bringing together scientific, policy, diplomatic, and business leaders to celebrate our commitment to science and public awareness.

Thank you to the many scientists and donors who make our work possible. Together, along with all of us at BrightFocus, we are united in an unwavering belief that, through the power of scientific research, there will be a day when women and men everywhere will live full and vibrant lives free from diseases of mind and sight.

STACY PAGOS HALLER
President and CEO

SCOTT D. RODGVILLE, CPA
Chair, Board of Directors

BrightFocus® Foundation
Cure in Mind. Cure in Sight.

- LOOKING AT A PROTEIN THAT ACCUMULATES IN THE BRAIN **PG 5**
- THE DRUG L-DOPA MAY PROTECT AGAINST AMD **PG 7**
- MAPPING A MISSING ENZYME **PG 9**

Our Mission

BrightFocus drives innovative research worldwide and promotes awareness of Alzheimer's, macular degeneration, and glaucoma.

Cutting-Edge Research with Personal Impact.

BrightFocus Foundation's three scientific research programs to end diseases of mind and sight:

- Alzheimer's Disease Research
- Macular Degeneration Research
- National Glaucoma Research



AT LEAST **1 in 16** PEOPLE IN THE U.S. OVER THE AGE OF 40 HAS ONE OR MORE OF THESE THREE DISEASES.

Demo of citizen scientist project at BrightFocus awards dinner.

Innovative and Engaging Research For The Cure.

Alzheimer's disease today affects more than five million Americans. Every 66 seconds, another American develops the disease, making it the sixth leading cause of death in the United States, and the only leading cause of death that has significantly increased in recent years. Alzheimer's has no known cause or cure.

This year, our Alzheimer's Disease Research program awarded more than $6.8 million to 32 new science projects. Since inception, the program has awarded more than $100 million. This research is leading us to a greater understanding of the disease and is moving us closer to a cure.

- WE AWARDED MORE THAN **$6.8 MILLION TO 32 NEW SCIENCE PROJECTS**

A BrightFocus-funded research project is working to better study the effects of Alzheimer's on the brain. We are helping launch EyesOnALZ, a new online tool for citizen scientists across the globe to help us map the brain. By engaging the public, we can advance our knowledge base much more quickly while also providing greater awareness of the disease.

EyesOnALZ

A Growing Epidemic



BrightFocus hosts inaugural Montgomery County (MD) DFA meeting.

Working Toward a Dementia Friendly America

BrightFocus recently joined a broad coalition of nonprofit and business leaders to launch Dementia Friendly America (DFA), a national movement creating communities that better recognize and serve Americans with dementia.

Announced at the White House Conference on Aging, DFA unites leaders from government, business, health care, and community groups to develop and implement a coordinated, compassionate approach to improving the quality of life for those affected by dementia.

Through the leadership and support of BrightFocus, Montgomery County, MD, home of our headquarters, was one of the earliest localities to join the DFA movement. Now more than 100 communities, ranging from cities to entire states, have begun to implement the DFA model.

Dementia Friendly America

www.dfamerica.org

Researcher Spotlight

A Grandfather Plants the Seeds of Research

For **Daniel Lee, PhD, University of South Florida**, the personal is professional. His distinguished career in neuroscience—a founding faculty member of the USF College of Pharmacy and Pharmaceutical Sciences who has won numerous research awards—began with the story of his grandfather.

As a young man, Lee could not understand "why my grandfather, who was a well-educated medical doctor, contracted Alzheimer's disease." During Lee's college years, his grandfather was also diagnosed with Parkinson's. Lee decided to pursue a doctorate in neuropharmacology, which studies the effects of drugs on the nervous system.

With the funding he received from Alzheimer's Disease Research, Lee is looking at molecules known as polyamines that appear to influence the presence of tau—a protein that accumulates in the brain in Alzheimer's. He hopes to help identify strategies for ending toxic tau build-up.

Lee's grandfather "planted the seed of health care in our family," recalls Lee, one of six other family members who went into the health field. "There is an innate drive to find cures for these devastating diseases."

Daniel Lee, PhD
University of South Florida

DR. LEE HOPES TO HELP **IDENTIFY STRATEGIES FOR ENDING TOXIC TAU BUILD-UP**

Macular Degeneration Research

Using the Power of Science to Stop Vision Loss.

- **WE AWARDED 20 NEW RESEARCH GRANTS TOTALING MORE THAN $3 MILLION**

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the United States, and for Caucasians older than 40, it is the leading cause of legal blindness. An estimated 11 million Americans have AMD, including the early and later stages of the wet and dry types of the disease.

This year Macular Degeneration Research awarded 20 new research grants totaling more than $3 million. Since its inception, the program has awarded more than $21 million supporting research into the causes and potential treatments of this widespread disease.

BrightFocus shares scientific news from researchers worldwide through multiple channels including our open-access, online journal, *Molecular Neurodegeneration*. At the annual conference of the Association for Research in Vision and Ophthalmology, BrightFocus pays tribute to our outstanding vision disease researchers, and we are pleased to support the Helen Keller Prize for Vision Research.



Monthly Tips for Families and Caregivers

We offer a monthly telephone call-in series, BrightFocus Chats, featuring researchers, clinicians, patients, and low-vision specialists who provide the latest tips and advice for those living with vision loss. The Chats, which foster an ongoing dialogue to address the questions and concerns of callers, are archived and available on our website.

A longtime Chat participant, Sally from Union, New Jersey, says, "I am a regular listener to all of these BrightFocus Chats. I have AMD and I find this to be a wonderful, wonderful, informative resource."

BrightFocus® Chats

Researcher Spotlight

The Benefits of Big Data: Bringing Us Closer to a Cure

Brian McKay, PhD, University of Arizona, was senior author of a study that made news in 2015 when it found that L-DOPA, a drug used to treat Parkinson's disease, may help protect against age-related macular degeneration (AMD).

The groundbreaking report, funded in part by Macular Degeneration Research and published in the *American Journal of Medicine*, looked at massive amounts of medical data for 87 million patients. McKay's team discovered that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was delayed.

In addition to this breakthrough, McKay is investigating in his BrightFocus grant how eye health is affected by L-DOPA signaling through a receptor near the retina. Understanding this process may help uncover how AMD begins—and how it might be stopped.

Clinical trials are needed to test his team's L-DOPA findings. As McKay told *U.S. News and World Report*, "I think in the end we are going to be able to prevent AMD, but we have more work to do."

Brian McKay, PhD
University of Arizona

Rods and cones in mini human retinas, from the lab of Dr. Canto-Soler.

National Glaucoma Research

Protecting Sight from Glaucoma.

Glaucoma is a group of eye diseases that damage the optic nerve and, without treatment, can result in vision loss and blindness. According to the World Health Organization, glaucoma is the second leading cause of irreversible blindness worldwide.

For Hispanics and African-Americans in the United States, glaucoma is the leading cause of blindness. Permanent vision loss can occur without any symptoms. BrightFocus is educating Americans across multiple platforms on the importance of scheduling a regular eye exam. From a social media "Thunderclap" campaign to TV and billboard public service announcements across the country, we are working to protect sight.

This year, National Glaucoma Research awarded 13 new research grants totaling more than $1.8 million. The program has awarded more than $28 million since inception.

- **WE AWARDED 13 NEW RESEARCH GRANTS TOTALING MORE THAN $1.8 MILLION**

Save Your Sight From Glaucoma



THUNDERCLAP **Protect Your Sight Campaign**

"Permanent vision loss can occur without any symptoms. Schedule an eye exam."

#worldsightday

SUPPORTERS
100+

AUDIENCE REACHED
350,000+

Expanding Our Digital Footprint

New BrightFocus website

To better share the latest scientific news and better provide access to our extensive library of public education materials, BrightFocus recently launched a new, more user-friendly website. At BrightFocus.org, all of our materials can be viewed with increased font size, downloaded free of charge or ordered in hard copy. We also provide helpful information via video and podcast, and are active on many social media channels including Facebook and Twitter.

Resources for Caregivers

BrightFocus recently released a new publication to support families and caregivers of those affected by glaucoma.

E-mail info@brightfocus.org to receive a free copy of the *Glaucoma: Treatment Options* brochure.

Researcher Spotlight

Mapping How an Enzyme Can Go Missing

Thanks to National Glaucoma Research, **Raquel Lieberman, PhD, of Georgia Tech**, and her team, have been able to provide a three-dimensional view of a protein linked to inherited forms of glaucoma.

Genetic mutations cause the protein, myocilin, to clog the eye's drainage system, causing increased eye pressure and impaired vision. With the 3-D depiction, Lieberman's team hopes to map the myocilin molecule, to help develop drugs that prevent its disease-causing variations.

Lieberman is inspired by a close friend, who suffers from a disorder known as Gaucher Disease, and is alive today because of enzyme replacement therapy. As a child, the friend was in the original clinical trial of a man-made form of an enzyme missing in Gaucher. She still takes the medication.

"It's her courage, and the commitment of her family to move from South Africa to Maryland in the hopes of a cure for their child, that motivates me every day in my work to combat human disease," said Lieberman.

DR. LIEBERMAN'S TEAM PROVIDES A THREE-DIMENSIONAL VIEW OF A PROTEIN LINKED TO INHERITED FORMS OF GLAUCOMA

Raquel Lieberman, PhD, of Georgia Tech

2016 BrightFocus Grant Recipients

Most grant awards last for two to three years. These 65 new grants collectively will contribute to a nearly $30 million research portfolio of 150 awards.

Alzheimer's Disease Research

Iman Aganj, PhD
New Methods to Account for Indirect Brain Connections and Improve the Accuracy of the Imaging Biomarkers for Alzheimer's Disease
MASSACHUSETTS GENERAL HOSPITAL

Rachel Bennett, BS, PhD
Blood Vessel Changes in Tauopathy
MASSACHUSETTS GENERAL HOSPITAL
This grant is made possible in part by a bequest from the Trust of Ida R. Kreingold.

Jason Brandt, PhD
Feasibility and Efficacy of a High Fat, Low Carbohydrate Diet for MCI and Early Alzheimer's Disease
JOHNS HOPKINS UNIVERSITY
This grant is made possible in part by support from the Jerome Jacobson Foundation.

Jennifer Gatchel, MD, PhD
Depressive Symptoms, Alzheimer's Disease (AD) Proteins Aß and Tau, and Neuronal Network Activity in Prodromal and Early AD
MCLEAN HOSPITAL
This grant is made possible by a bequest from the Howlett Revocable Trust.

Swetha Gowrishankar, PhD
Role of Axonal Lysosome Transport in Alzheimer's Disease Pathology
YALE UNIVERSITY

Jean-Vianney Haure-Mirande, PhD
Role of Microglia in Alzheimer's Disease: Deleterious or Helpful?
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
This grant is made possible by support from the J.T. Tai Foundation.

Mark Henkemeyer, PhD
Identification of Novel Compounds to Promote Synapse Health and Prevent Alzheimer's Disease
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Joachim Herz, MD
Targeting the Molecular Cause of the ApoE4-risk in Alzheimer's Disease
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Tsuneya Ikezu, MD, PhD
Validation of Drug Candidates for Enhancing the Phagocytic Clearance in the Alzheimer's Brain
BOSTON UNIVERSITY

David Irwin, MD, MS
Non-Amnestic Alzheimer's Disease Biology
UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE

Xiong Jiang, PhD
A Novel Non-Invasive MRI-Based Biomarker of Early Stages of Alzheimer's Disease
GEORGETOWN UNIVERSITY

Catherine Kaczorowski, PhD
A New Method to Identify Genes Critically Involved in Alzheimer's Disease
THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER

Patrick Kehoe, BSc, PhD
Helping the Brain to Fight Back Against Alzheimer's Disease—Using Old Drugs for New Purposes
UNIVERSITY OF BRISTOL (UK)
This grant is made possible in part by a bequest from the Trust of Edward & Irene Schlosser.



2016 BrightFocus Grants at a Glance



Doo Yeon Kim, PhD
A Human Cellular Alzheimer's Disease Model Based on 3D Culture Technology
MASSACHUSETTS GENERAL HOSPITAL

Chia-Chen Liu, PhD
The Virginia Faber Memorial Award for Alzheimer's Disease Research
The Effects of APOE Isoforms on Brain Functions and Alzheimer's Disease
MAYO CLINIC JACKSONVILLE

Selene Lomoio, PhD
Reorganizing the Neuronal Highway in the Alzheimer's Brain
TUFTS UNIVERSITY SCHOOL OF MEDICINE

Brendan Lucey, MD
Sleep Quality and Decreasing Aß Levels in the Human Brain
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Constantine Lyketsos, MD
Accelerating the Development, Testing, and Dissemination of Home-Based Dementia Care Interventions
JOHNS HOPKINS UNIVERSITY

Wenjie Luo, PhD
Cellular Mechanisms Underlying Microglia-Mediated Amyloid Degradation
WEILL CORNELL MEDICAL COLLEGE

Zixu Mao, PhD
Understanding Brain Inflammation in Alzheimer's Disease
EMORY UNIVERSITY

Stephen Martin, PhD
A New Approach to Treating Alzheimer's Disease
THE UNIVERSITY OF TEXAS AT AUSTIN
This grant is made possible in part by a bequest from the Trust of Francis C. Dykeman and in honor of Marie E. Dykeman.

Pietro Michelucci, PhD
Crowd-powered Microvascular Modeling
HUMAN COMPUTATION INSTITUTE

Ana Pereira, MD
Enhancing Glutamate Levels as a Way to Treat Alzheimer's Disease
THE ROCKEFELLER UNIVERSITY
This grant is made possible in part by support from the Ping Y. Tai Foundation.

Dianne Perez, PhD
Novel Drugs against a New Receptor Target to Treat Alzheimer's Disease
THE CLEVELAND CLINIC FOUNDATION

Emilie Reas, PhD
Novel Biomarkers of Brain Microstructure in Aging and Mild Cognitive Impairment
UNIVERSITY OF CALIFORNIA, SAN DIEGO

Jiri Safar, MD
Profiling Prion-Like Strains of Aß that Control Alzheimer's Progression
CASE WESTERN RESERVE UNIVERSITY

Stephen Salton, MD, PhD
Role of VGF in Alzheimer's Disease Pathogenesis and Progression
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Paul Seidler, PhD
Blocking Assembly of Tau Protein into Toxic Structures Associated with Alzheimer's
UNIVERSITY OF CALIFORNIA, LOS ANGELES

Qiaoqiao Shi, PhD
New Mouse Models to Study the Role of Complement in Brain Aging and Neurodegeneration
BRIGHAM AND WOMEN'S HOSPITAL
This grant is made possible in part by a bequest from the Estate of Frederick J. Pelda.

Tara Tracy, PhD
Investigating the Impact of KIBRA Protein Loss on Synapse Function and Memory
THE J. DAVID GLADSTONE INSTITUTES

Laura Wisse, PhD
Separating Early AD and Aging Effects in Search of Markers to Track Alzheimer's Treatment Effects
UNIVERSITY OF PENNSYLVANIA
This grant is made possible in part by a bequest from the Trust of Elenore Lundeen.

Huda Zoghbi, MD
A Genetic Screen to Identify New Drug Targets for Alzheimer
BAYLOR COLLEGE OF MEDICINE

National Glaucoma Research

Audrey Bernstein, PhD
Use of Patient-Derived Cells to Test Compounds that Will Reverse Exfoliation Glaucoma
ICAHN MOUNT SINAI SCHOOL OF MEDICINE

Kevin Chan, PhD
Early Brain Changes and Visual and Motor Functions in Glaucoma
UNIVERSITY OF PITTSBURGH

J. Crawford Downs, PhD
A Wireless System to Measure and Control Fluid Pressure Around the Optic Nerve
UNIVERSITY OF ALABAMA AT BIRMINGHAM

Rudolf Fuchshofer, PhD
Identifying Underlying Pressure-Control Mechanisms in Glaucoma
UNIVERSITY OF REGENSBURG (GERMANY)

Haiyan Gong, MD, PhD
Mechanism of Decreased Giant Vacuole and Pore Formation in Glaucoma Using a Novel Method
BOSTON UNIVERSITY SCHOOL OF MEDICINE

Meredith Gregory-Ksander, PhD
The Thomas R. Lee Award for Glaucoma Research
A New Method to Inhibit Inflammation and Prevent Glaucoma
SCHEPENS EYE RESEARCH INSTITUTE, MASSACHUSETTS EYE AND EAR

Shahid Husain, PhD
Low Oxygen Mediated Proteins Play Pathological Role in Glaucoma
MEDICAL UNIVERSITY OF SOUTH CAROLINA

Raquel Lieberman, PhD
Function and Dysfunction of Myocilin in Glaucoma: New Insight from Proteomics
GEORGIA INSTITUTE OF TECHNOLOGY

Yutao Liu, MD, PhD
Identifying New Drug Targets to Lower Eye Pressure Via Outflow
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

Gillian McLellan, PhD
A New Treatment to Protect the Optic Nerve in Glaucoma
UNIVERSITY OF WISCONSIN

Xiuqian Mu, MD, PhD
Generating Retinal Ganglion Cells in a Dish to Study and Treat Glaucoma
SUNY, BUFFALO

Yvonne Ou, MD
The Douglas H. Johnson Award for Glaucoma Research
Understanding the Earliest Steps of Optic Nerve Cell Death in Glaucoma
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Daniel Sun, PhD
Astrocyte Reactivity in the Glaucomatous Optic Nerve Head: Beneficial or Harmful for Vision?
SCHEPENS EYE RESEARCH INSTITUTE, MASSACHUSETTS EYE AND EAR

2016 BrightFocus Grant Recipients (continued)

Macular Degeneration Research

Paul Baird, PhD
Identifying Gene Pathways in Late-Stage AMD
CENTRE FOR EYE RESEARCH AUSTRALIA, THE UNIVERSITY OF MELBOURNE

Brian Ballios, MD, PhD
Biomaterial-Based Stem Cell Therapies for Blinding Eye Disease
UNIVERSITY OF TORONTO (CANADA)
This grant is made possible in part by a bequest from the Trust of Edward Primet.

Petr Baranov, MD, PhD
A New Approach to Rescuing Photoreceptors from Death through Activation of Endogenous Neuroprotective Mechanisms
SCHEPENS EYE RESEARCH INSTITUTE, MASSACHUSETTS EYE AND EAR

Vera Bonilha, PhD
Atrophic Lesion Borders in AMD: What Can They Tell Us?
THE CLEVELAND CLINIC FOUNDATION
This grant is made possible in part by a bequest from the Trust of Edna Stuver-Webster.

Maria Valeria Canto-Soler, PhD
The Helen Juanita Reed Award for Macular Degeneration Research
A New Model of a Human Retina in a Dish to Study AMD
JOHNS HOPKINS UNIVERSITY

Kip Connor, PhD
Lipid Regulators of AMD
SCHEPENS EYE RESEARCH INSTITUTE, MASSACHUSETTS EYE AND EAR
This grant is made possible in part by a bequest from the Estate of Robert J. Mac.

Patrick Daugherty, PhD
Characterization of Circulating Antibodies Specific to AMD
UNIVERSITY OF CALIFORNIA, SANTA BARBARA

Sarah Doyle, PhD
Investigating How Loss of an "Off Switch" for Inflammation Contributes to AMD
TRINITY COLLEGE DUBLIN (IRELAND)

Jianhai Du, PhD
A New Method to Decrease Cell Death by Supplementation with NAD Metabolites
WEST VIRGINIA UNIVERSITY
This grant is made possible in part by support from the Ivan Bowen Family Foundation.

Malia Edwards, PhD
A Study of Why Retinal Support Cells, Called Glia, Exit the Retina in AMD
JOHNS HOPKINS UNIVERSITY
This grant was made possible in part by a bequest from the Robert H. McLaren Trust.

Kaustabh Ghosh, PhD
Understanding the Role of Increased Cell Stiffness in Cell Death Associated with AMD
UNIVERSITY OF CALIFORNIA, RIVERSIDE

Francesco Giorgianni, PhD
Basic and Clinical Studies to Understand the Role of the CD5L/AIM Protein in AMD
THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
This grant is made possible in part by a bequest from the Stuart Blydenburgh Trust.



Amyloid plaques, from the lab of Dr. Gowrishankar

Jeffrey Gross, PhD
Identification of Factors that Can Stimulate Regeneration of the RPE
UNIVERSITY OF PITTSBURGH

Robyn Guymer, MBBS, PhD
The Carolyn K. McGillvray Memorial Award for Macular Degeneration Research
Too Much Debris as a Cause of AMD
CENTRE FOR EYE RESEARCH AUSTRALIA, THE UNIVERSITY OF MELBOURNE

Zhihong Hu, PhD
An Automated Method to Detect and Analyze Atrophic Lesions in AMD
DOHENY EYE INSTITUTE, UCLA

John Hulleman, PhD
A Single Genetic Manipulation for Treating ML/Dry AMD
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
This grant is made possible in part by a bequest from the Trust of Anne E. Greene.

Benjamin Kim, MD
Therapeutic Evaluation of Alpha Lipoic Acid for Geographic Atrophy
UNIVERSITY OF PENNSYLVANIA

Marcelo Nociari, PhD
Identification of Novel Treatments for Macular Degeneration by Alleviating Endoplasmic Reticulum Stress
WEILL CORNELL MEDICAL COLLEGE

Debasish Sinha, PhD
Novel Therapeutic Targets for the Treatment of Early AMD
JOHNS HOPKINS UNIVERSITY

Biju Thomas, PhD
Functional Benefits of Polarized iPS-RPE Monolayer Transplantation Assessed in a New Immunodeficient RPE Dysfunction Rat Disease Model
UNIVERSITY OF SOUTHERN CALIFORNIA EYE INSTITUTE
This grant is made possible by a bequest from the Estate of Jane M. Simon.

BrightFocus Scientific Review Committees

Our world-class scientific review committees recommend BrightFocus research grants on the basis of scientific merit with the goal of discovering a treatment or cure for Alzheimer's, macular degeneration, and glaucoma.

We encourage researchers to propose their groundbreaking ideas.

Alzheimer's Disease Research

Co-Chairs:

David R. Borchelt, PhD
University of Florida

Edward Koo, MD
University of California, San Diego

Committee Members:

M. Flint Beal, MD
The New York Hospital-Cornell Medical Center

Guojun Bu, PhD
Mayo Clinic, Jacksonville

George Carlson, PhD
McLaughin Research Institute

Mark D'Esposito, MD
University of California, Berkeley

Steven Estus, PhD
University of Kentucky

Matthew Frosch, MD, PhD
Massachusetts General Hospital

Douglas Galasko, MD
University of California, San Diego

Charles G. Glabe, PhD
University of California, Irvine

Alison M. Goate, DPhil
Icahn School of Medicine at Mount Sinai

Yukiko Goda, PhD
RIKEN Brain Science Institute (Japan)

Todd E. Golde, MD, PhD
University of Florida

John Hardy, PhD, FMedSci, FRS
University College London

Julie Harris, PhD
Allen Institute for Brain Science

David Holtzman, MD
Washington University School of Medicine

William Jagust, MD
University of California, Berkeley

John "Keoni" Kauwe, PhD
Brigham Young University

Cynthia A. Lemere, PhD
Harvard Medical School, Brigham and Women's Hospital

Allan I. Levey, MD, PhD
Emory University

Ronald K. Liem, PhD
Columbia University

Hendrik Luesch, PhD
University of Florida

John M. Olichney, MD
University of California, Davis

David P. Salmon, PhD
University of California, San Diego

Gerard Schellenberg, PhD
University of Pennsylvania School of Medicine

Jane Sullivan, PhD
University of Washington School of Medicine

Rudolph Tanzi, PhD
Massachusetts General Hospital

David B. Teplow, PhD
University of California, Los Angeles

Gopal Thinakaran, PhD
University of Chicago

Ronald B. Wetzel, PhD
University of Pittsburgh

Tony Wyss-Coray, PhD
Stanford University Medical School

Kristine Yaffe, MD
University of California, San Francisco

Riqiang Yan, PhD
Cleveland Clinic Foundation

Hui Zheng, PhD
Baylor College of Medicine



We have a rigorous peer-review process in which renowned scientific leaders identify the most promising research to support.

BrightFocus Scientific Review Committees (continued)

National Glaucoma Research

Chair:

Joe G. Hollyfield, PhD
The Cleveland Clinic Foundation

Interim Chair for FY16:

Michael B. Gorin, MD, PhD
University of California, Los Angeles

Committee Members:

Bela Anand-Apte, PhD
The Cleveland Clinic Foundation

Robert E. Anderson, MD, PhD
University of Oklahoma Health Sciences

John D. Ash, PhD
University of Florida

Alan Bird, MD
University College London

Catherine Bowes-Rickman, PhD
Duke University

Deborah Ferrington, PhD
University of Minnesota

Steven Fliesler, PhD
SUNY, Buffalo

Claire Harris, PhD
Cardiff University (Wales)

Alfred S. Lewin, PhD
University of Florida

John Penn, PhD
Vanderbilt University School of Medicine

Nancy J. Philp, PhD
Thomas Jefferson University

Sylvia B. Smith, PhD
Augusta University

Debra Thompson, PhD
University of Michigan

Macular Degeneration Research

Chair:

John C. Morrison, MD
Oregon Health & Science University

Committee Members:

R. Rand Allingham, MD
Duke University

Claude F. Burgoyne, MD
Devers Eye Institute

Abbot F. Clark, PhD
University of North Texas

Anne L. Coleman, MD, PhD
University of California, Los Angeles

Adriana DiPolo, PhD
University of Montreal (Canada)

C. Ross Ethier, PhD
Georgia Institute of Technology and Emory School of Medicine

Thomas F. Freddo, OD, PhD
University of Waterloo (Canada)

Jeffrey L. Goldberg, MD
Stanford University

Richard Libby, PhD
University of Rochester Medical Center

Nicholas Marsh-Armstrong, PhD
Johns Hopkins University

Stuart J. McKinnon, MD, PhD
Duke University

Robert W. Nickells, PhD
The University of Wisconsin

Ian Sigal, PhD
University of Pittsburgh School of Medicine

Arthur J. Sit, MD
Mayo Clinic, Rochester

W. Daniel Stamer, PhD
Duke University

James N. Ver Hoeve, PhD
University of Wisconsin

Monica Vetter, PhD
Indiana University

Mary Wirtz, PhD
Oregon Health & Science University

Darrell WuDunn, MD, PhD
Indiana University

Partnerships For A Cure

BrightFocus works closely with nonprofits and corporations alike to advocate for those impacted by Alzheimer's disease, macular degeneration, and glaucoma. We collaborate with partners in advocacy coalitions, and interact with key policymakers and elected officials on behalf of greater allocation of federal resources and support for caregivers.

21CBT
21st Century Braintrust
Alcon
a Novartis company
CentraSight
Restore the Center of Your World
Delta Gamma Foundation
for hope, for strength, for life.
echo
by Eyemaginations
Geoffrey Beene Foundation
GBFAI
Alzheimer's Initiative
Genentech
A Member of the Roche Group
Goldman Sachs
Home Instead
Senior Care
To us, it's personal.
LEAD
Leaders Engaged on Alzheimer's Disease

Lilly
Molecular Neurodegeneration
NAEVR
National Alliance For Eye And Vision Research
Serving as Friends of the National Eye Institute
NOTAL VISION™
Your Sight is Our Vision
PNC BANK
REGENERON
science to medicine™
RKD
Robbins Kersten Direct
Boston • Dallas
Sage
Bionetworks
Sandy Spring Bank
From here. For here.
TrialReach
US Against Alzheimer's
Network

Global Network for Alzheimer's

BrightFocus partners with four European countries to generate critical funding and create public awareness to advance research and educate millions around the globe about Alzheimer's disease.

★ **Belgium**
Stichting Alzheimer Onderzoek

★ **France**
Ligue Europeenne Contre
La Maladie d'Alzheimer

★ **Germany**
Alzheimer Forschung Initiative e.V.

★ **The Netherlands**
Internationale Stichting
Alzheimer Onderzoek

Investing In A Cure

On behalf of current and future generations, who benefit from the research funded by Alzheimer's Disease Research, Macular Degeneration Research and National Glaucoma Research, BrightFocus Foundation thanks our generous donors for investing in a cure for current and future generations. We are fortunate to be supported by so many individuals, private foundations and corporations for our programs that advance research and promote public awareness.

We offer a wide range of contribution opportunities to accommodate resources and charitable goals. Each and every gift is important and needed to help find a cure and educate the community.

BrightFocus featured on BBB's Wise Giving Alliance Building Trust *Series*

Sowing the Seeds of Scientific Progress

BrightFocus-funded researchers often go on to receive awards ten times greater from NIH and other sources, a 1,000% return on our early investment.

Donor Spotlight

Many BrightFocus donors have special connections to the research programs they support. We are honored to share three of those stories with you.

Increasing Opportunities for Clinical Trials: A Strategic Investment

Barry Friedberg, president and CEO of FriedbergMilstein, LLC, an independent investment management firm in New York City, has served in a range of leadership positions in the world of finance over the past 50 years, including leadership of the Global Banking Investment Business of Merrill Lynch in the 1980s and 1990s. He also has a wide range of philanthropic interests, from supporting educational and arts organizations to youth development.

Mr. Friedberg has personal reasons for donating to our National Glaucoma Research (NGR), a program of BrightFocus Foundation. His mother had glaucoma, and lost most of her eyesight from the disease. Now Friedberg has glaucoma. He takes a regimen of medications for his left eye, and had procedures that remove a tiny portion of the eye's meshwork to allow better drainage. He remains active, continuing his love of skiing and golfing.

Through a generous donation to NGR, Friedberg will help support the Phase II clinical trial of ciliary neurotrophic factor—a molecule known to promote protection and regeneration of retinal ganglion cells in models of glaucoma.

Says Friedberg, "If I can make a difference in the advancement of glaucoma research and the speed of clinical trials to end this disease, I believe that is a sound investment."

John O'Brien, BrightFocus Foundation, visited the Praise Team to thank them for their donation.

Honoring Their Friend's Great-Grandfather: Young Dancers Give Hope

Bonnie Walker, owner and artistic director of Next Step School of Dance in New Jersey, says she teaches young dancers on her Praise Team that, "we need to reach out to the causes that need our assistance."

Each month, the Praise Team brings their ideas to class and, through discussion and prayer, decides on an organization to receive the team donation. In spring 2016, Nicolette Zika, age 13, spoke about her great-grandfather, Alberto Lazaro Sr., and how his death from Alzheimer's had affected her family.

She shared information about the Alzheimer's Disease Research program (ADR), which her mother, Dina Marie Zika, has donated to since 2007. In honor of Nicolette's great-grandfather, the young dancers selected ADR for their donation.

As Bonnie noted, "We have been able to let a family that has lost a loved one to this disease know how much we care about them."

The team's support for Alzheimer's research also represented hope. Wrote Nicolette and Dina, "We truly hope that someday we will find a cure, not only for individuals, but also for their families."

Educating Others, Leaving a Legacy

Lynne uses magnifying lenses and binoculars to help her see.

Lynne Rubin, 94, of Queens, New York, began having vision problems in her left eye almost 30 years ago. Her doctor at the time diagnosed her with a virus. It was not until years later that an ophthalmologist officially diagnosed her with dry macular degeneration. Lynne learned all she could about the disease and shared that knowledge, speaking at libraries and hospitals. Her message: "See your ophthalmologist every year."

She has been a loyal supporter of BrightFocus Foundation's Macular Degeneration Research (MDR) program. Lynne applauds the program's research efforts, and loves the informative publications, which she sends to her doctors and friends. She also participates in the monthly BrightFocus Chats that provide timely information on vision disease.

MDR "does an excellent job of supporting research and educating the public about macular degeneration," says Lynne. That's why she is leaving a gift to MDR in her estate plan, and is now a member of BrightFocus Foundation's Heritage Society.

Financial Highlights

BrightFocus is a nonprofit organization designated under Section 501(c)(3) of the Internal Revenue Code. All contributions to BrightFocus and its programs are tax-deductible to the extent allowed by law. The foundation is supported entirely by voluntary private contributions.

BrightFocus Foundation 2016 Expense Percentages



*BrightFocus received in-kind donations to expand public health information outreach and these are included in Program Services expenses. This allowed the organization to reach millions of people with information about risk factors, treatments, and caregiving.

A complete copy of the financial statement audited by Raffa, P.C., is available upon request from BrightFocus at 1-800-437-2423 or www.brightfocus.org.

Consolidated Statement of Financial Position

As of March 31, 2016 *(in thousands of dollars)*

ASSETS	
Cash and Investments	$37,818
Charitable Trusts and Bequests Receivable	5,569
Rental Property	3,928
Fixed Assets, Net	4,693
Other Assets	1,268
TOTAL ASSETS	**$53,276**

LIABILITIES	
Accounts Payable and Other Liabilities	$976
Grants Payable	20,173
Charitable Gift Annuities	1,267
TOTAL LIABILITIES	**$22,416**

NET ASSETS	
Unrestricted	$19,794
Temporarily Restricted	10,976
Permanently Restricted	90
TOTAL NET ASSETS	**$30,860**
TOTAL LIABILITIES AND NET ASSETS	**$53,276**

Consolidated Statement of Activities

For the Fiscal Year Ended March 31, 2016 *(in thousands of dollars)*

SUPPORT & REVENUE	
Contributions and Grants	$22,501
Bequests	6,720
Donated Services	13,318
Investment Loss	(1,151)
Rental & Other Income	886
TOTAL SUPPORT & REVENUE	**$42,274**

EXPENSES	
PROGRAM SERVICES	
Research	$15,069
Health Information Services	21,077
TOTAL PROGRAM EXPENSES	**$36,146**
SUPPORTING SERVICES	
Fundraising	$5,667
Management and General	2,766
TOTAL SUPPORTING SERVICES	**$8,433**
TOTAL EXPENSES	**$44,579**
CHANGE IN NET ASSETS	**$(2,305)**

Leadership

BrightFocus Board of Directors

Chair
Scott D. Rodgville, CPA
Gorfine, Schiller & Gardyn, PA
Owings Mills, MD

Vice Chair
Diane I. Marcello
Sunnyside Health Services
Sarasota, FL

Treasurer
Nicholas W. Raymond
USA (Ret.)
M&T Bank, retired
Silver Spring, MD

Secretary
Judith Lee
J. P. Morgan & Co., Inc., retired
Nantucket, MA

Michael H. Barnett, Esq.
Lieber & Associates, LLC
New York, NY

Maddy Dychtwald
Age Wave
San Francisco, CA

Grace Frisone
J. P. Morgan & Co., Inc., retired
Saratoga Springs, NY

June Kinoshita
Facioscapulohumeral Muscular Dystrophy Society
Waltham, MA

Henry J. Pownall, PhD
Houston Methodist Research Institute
Houston, TX

Honorary Members

Brian K. Regan, PhD
New York-Presbyterian Hospital and Healthcare System
New York, NY

Ed Schoonveld
ZS Associates
New York, NY

Ethan Treese
Dun & Bradstreet
Washington, DC

Paul A. Greengard, PhD
Nobel Laureate
New York, NY

Stanley B. Prusiner, MD
Nobel Laureate
San Francisco, CA

Our Senior Management Team

PRESIDENT & CEO
Stacy Pagos Haller

VICE PRESIDENT, SCIENTIFIC AFFAIRS
Diane Bovenkamp, PhD

VICE PRESIDENT, PUBLIC AFFAIRS
Michael Buckley

SENIOR VICE PRESIDENT, DEVELOPMENT
R. Brian Elderton

SENIOR VICE PRESIDENT, STRATEGIC PARTNERSHIPS
Nancy Lynn

VICE PRESIDENT, FINANCE AND ADMINISTRATION
David F. Marks, CPA, CMA

BrightFocus® Foundation

Cure in Mind. Cure in Sight.

Programs

Alzheimer's Disease Research
Macular Degeneration Research
National Glaucoma Research

Contact

22512 Gateway Center Drive
Clarksburg, MD 20871
1-800-437-2423

Integrity

America's Charities®

BBB ACCREDITED CHARITY

Valued Partner GuideStar Exchange PARTNERS IN TRUST

MARYLAND NONPROFITS STANDARDS FOR EXCELLENCE

Connect

www.brightfocus.org